Identification of patterns of factors preceding severe or life-threatening asthma exacerbations in a nationwide study


  • Funding information

    This work was performed by a collaboration between the IAA research investigators and FBRI in Japan. The FBRI is a public interest incorporated foundation, committed to the promotion of translational and clinical research in Japan, receiving financial resources from pharmaceutical/medical device companies. This was an investigator-initiated clinical study with operational and technical support provided by the FBRI.

  • Edited by: Hans-Uwe Simon



Reducing near-fatal asthma exacerbations is a critical problem in asthma management.


To determine patterns of factors preceding asthma exacerbations in a real-world setting.


In a nationwide prospective study of 190 patients who had experienced near-fatal asthma exacerbation, cluster analysis was performed using asthma symptoms over the 2-week period before admission.


Three distinct clusters of symptoms were defined employing the self-reporting of a visual analogue scale. Cluster A (42.1%): rapid worsening within 7.4 hours from moderate attack to admission, young to middle-aged patients with low Body mass index and tendency to depression who had stopped anti-asthma medications, smoked, and hypersensitive to environmental triggers and furred pets. Cluster B (40.0%): fairly rapid worsening within 48 hours, mostly middle-aged and older, relatively good inhaled corticosteroid (ICS) or ICS/long-acting beta-agonist (LABA) compliance, and low perception of dyspnea. Cluster C (17.9%): slow worsening over 10 days before admission, high perception of dyspnea, smokers, and chronic daily mild-moderate symptoms. There were no differences in overuse of short-acting beta-agonists, baseline asthma severity, or outcomes after admission for patients in these 3 clusters.


To reduce severe or life-threatening asthma exacerbation, personalized asthma management plans should be considered for each cluster. Improvement of ICS and ICS/LABA compliance and cessation of smoking are important in cluster A. To compensate for low perception of dyspnea, asthma monitoring of peak expiratory flow rate and/or exhaled nitric oxide would be useful for patients in cluster B. Avoidance of environmental triggers, increase usual therapy, or new anti-type 2 response-targeted therapies should be considered for cluster C.